Renaissance Technologies’s UroGen Pharma URGN Stock Holding History

Renaissance Technologies’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.59M	Buy	+70,300	New	+$1.91M	﹤0.01%	1824
2026 Q1	–	Sell	-244,300	Closed	-$5.72M	–	3708
2025 Q4	$5.72M	Sell	244,300 -30,800	-11%	-$668K	0.01%	1218
2025 Q3	$5.49M	Buy	275,100 +236,900	+620%	+$4.25M	0.01%	1435
2025 Q2	$523K	Sell	38,200 -52,400	-58%	-$503K	﹤0.01%	2803
2025 Q1	$1M	Sell	90,600 -47,600	-34%	-$507K	﹤0.01%	2432
2024 Q4	$1.47M	Buy	+138,200	New	+$1.65M	﹤0.01%	2255
2024 Q1	–	Sell	-91,300	Closed	-$1.37M	–	4103
2023 Q4	$1.37M	Sell	91,300 -69,000	-43%	-$896K	﹤0.01%	2200
2023 Q3	$2.25M	Buy	160,300 +86,300	+117%	+$1.39M	﹤0.01%	1788
2023 Q2	$766K	Buy	74,000 +26,000	+54%	+$287K	﹤0.01%	2635
2023 Q1	$444K	Buy	48,000 +4,700	+11%	+$43.3K	﹤0.01%	2943
2022 Q4	$384K	Buy	43,300 +200	+0.5%	+$1.89K	﹤0.01%	3105
2022 Q3	$359K	Sell	43,100 -500	-1%	-$4.14K	﹤0.01%	3115
2022 Q2	$357K	Buy	43,600 +18,900	+77%	+$130K	﹤0.01%	3354
2022 Q1	$215K	Buy	+24,700	New	+$193K	﹤0.01%	3614
2021 Q1	–	Sell	-32,800	Closed	-$591K	–	3728
2020 Q4	$591K	Buy	+32,800	New	+$687K	﹤0.01%	2745
2019 Q2	–	Sell	-8,000	Closed	-$296K	–	3767
2019 Q1	$296K	Buy	+8,000	New	+$335K	﹤0.01%	3098
2018 Q4	–	Sell	-16,800	Closed	-$793K	–	3629
2018 Q3	$793K	Sell	16,800 -98,651	-85%	-$4.58M	﹤0.01%	2697
2018 Q2	$5.75M	Sell	115,451 -41,249	-26%	-$2.4M	0.01%	1699
2018 Q1	$7.79M	Buy	156,700 +25,600	+20%	+$1.28M	0.01%	1530
2017 Q4	$4.88M	Buy	131,100 +105,500	+412%	+$3.76M	0.01%	1824
2017 Q3	$807K	Buy	+25,600	New	+$565K	﹤0.01%	2645

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Renaissance Technologies's URGN Position: Q2 2026 in Review

Renaissance Technologies opened a new position in UroGen Pharma (URGN) in Q2 2026: 70,300 shares worth $2.59M. The stake represents ﹤0.01% of the portfolio and ranks #1824 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in URGN as recently as Q4 2025.

Renaissance Technologies first reported a position in URGN in Q3 2017 and has held it in 21 quarters since. The position peaked at $7.79M in Q1 2018. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Renaissance Technologies held 70,300 shares of UroGen Pharma worth $2.59M as of Q2 2026.
UroGen Pharma was a new Renaissance Technologies position in Q2 2026.
UroGen Pharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1824 holding.
Renaissance Technologies first reported a position in UroGen Pharma in Q3 2017 and has held it in 21 quarters since.
Renaissance Technologies's UroGen Pharma position peaked at $7.79M in Q1 2018.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.